Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Teclistamab for R/R myeloma

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses a Phase I study of teclistamab, a humanized b-cell maturation antigen (BCMA), CD3 bispecific antibody, for the treatment of relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).